Benjamin Hohl
Equibles does not estimate personal net worth.
Get an email with a short summary when Enliven Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ELVN alertsAbout Benjamin Hohl
Benjamin Hohl is recorded as CFO at Enliven Therapeutics, Inc. (ELVN). The newest filing on record that lists Benjamin Hohl as CFO at Enliven Therapeutics, Inc. (ELVN) is dated April 27, 2026. Enliven Therapeutics, Inc. reported in an 8-K filed March 1, 2023 that Benjamin Hohl was appointed Chief Financial Officer, effective February 23, 2023. Enliven Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Enliven Therapeutics, Inc. includes Richard Fair (CEO and Board Member), Rick Fair (CEO and Board Member), Sam Kintz, M.B.A. (CEO and Board Member) and 7 others.
“Pursuant to the Merger Agreement, on February 23, 2023, the Board appointed Sam Kintz, M.B.A, as President and Chief Executive Officer of the Company and Benjamin Hohl as Chief Financial Officer of the Company.”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 27, 2026
Company network
Leadership on record at Enliven Therapeutics, Inc.
- Richard Fair CEO, Board Member
- Rick Fair CEO, Board Member
- Sam Kintz, M.B.A. CEO, Board Member
- Samuel Kintz CEO
- Richard Heyman, Ph.D. Chairman, Board Member
- Ben Hohl CFO
- Anish Patel COO
- Andrew Phillips, Ph.D. Board Member
- Continuing Directors Board Member
- Jake Bauer Board Member